Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Eiger BioPharmaceuticals Inc | EIGR | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.725 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.725 | 1.725 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.10 - 43.35 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 1.725 | USD |
Eiger BioPharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 2.55M | - | - | - | -2.64 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Eiger BioPharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 4/01/2024 | 10:12 | GlobeNewswire Inc. | Eiger BioPharmaceuticals Files for Voluntary Chapter 11.. |
| 3/11/2024 | 15:03 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/24/2024 | 15:59 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/18/2024 | 16:49 | PR Newswire (US) | Eiger and Partner, AnGes, Receive Approval for Zokinvy®.. |
| 1/08/2024 | 06:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/04/2024 | 07:45 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/04/2024 | 07:00 | PR Newswire (US) | Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse.. |
| 12/11/2023 | 15:01 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements |
| 12/04/2023 | 05:01 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of.. |
| 12/01/2023 | 15:02 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements |
| 11/24/2023 | 05:01 | Edgar (US Regulatory) | Form SC 13D - General statement of acquisition of beneficial.. |
| 11/13/2023 | 15:01 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EIGR Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 1.85 | 2.8798 | 1.66 | 2.20 | 399,379 | -0.125 | -6.76% |
| 3 Months | 6.18 | 8.2672 | 1.10 | 2.03 | 161,686 | -4.46 | -72.09% |
| 6 Months | 8.43 | 14.337 | 1.10 | 5.95 | 181,930 | -6.71 | -79.54% |
| 1 Year | 31.50 | 43.35 | 1.10 | 16.40 | 301,180 | -29.78 | -94.52% |
| 3 Years | 256.80 | 300.639 | 1.10 | 121.97 | 426,852 | -255.08 | -99.33% |
| 5 Years | 321.90 | 474.60 | 1.10 | 185.16 | 381,115 | -320.18 | -99.46% |
Eiger BioPharmaceuticals Description
| Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3. |
